In a subsequent study conducted by the same research group, a reduction in tumour hypoxia in a HER2+ murine model under this agent was confirmed through PET imaging via 18F-FMISO, concluding on the potential of trastuzumab to improve tumour perfusion and deliver anti-cancer therapy [49]. The gene discussed is ERBB2; the disease is neoplasm.